Shareholders were too late in filing a lawsuit alleging that Eli Lilly and Co. concealed off-label marketing information as well as data about the risks of diabetes and other diseases linked to its schizophrenia drug Zyprexa, according to a ruling issued by a federal judge in New York. Lilly is "very pleased with the result" and was always convinced that the case had no merit, a spokesman said.

Full Story:

Related Summaries